Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: A dose-finding study

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 145-151

  Yang, Tsai Shen ^a   Chen, Jinn Shium ^a   Tang, Reiping ^a   Chiang, Jy Ming ^a   Hsieh, Pau Shiu ^a   Yeh, Chien Yu ^a   Changchien, Chung Rong ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Biweekly regimen; Bolus 5 fluorouracil; Colorectal cancer; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 0037331719     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00008     Document Type: Article

References (25)

1. Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987; 3:190-214.
2. Seifert P, Baker LH, Reed MD, Vaitkevicius VK. Comparison of continuous infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal carcinoma. Cancer 1975; 30:123-128.
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a bolus schedule in metastatic colorectal carcinomas. A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7:425-433.
4. Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99:823-833.
5. Yang TS, Hsu KC, Chiang JM, Tang R, Chen JS, Changchien CR, et al. A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. Cancer 1999; 85:1925-1930.
6. Meta-analysis Group in Cancer. Efficacy of continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 17:301-308.
7. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
8. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo C, Focan C, et al. Phase III multicenter randomized trial of oxalipratin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
9. Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Coppola F, et al. A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37:1006-1013.
10. De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219.
11. Andre T, Louvet C, Raymond E, Tournigand C, de Gramont. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FLOFOX-3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9:1251-1253.
12. Andre T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17:3560-3568.
13. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999; 35:1338-1342.
14. Chau I, Webb A, Cunningham D, Chau I, Hill H, Waters JS, Norman A, et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001; 85:1258-1264.
15. Bensmaine MA, de Gramont A, Brienza S, Marty M, Levi F, Ducreux M, et al. Factors predicting for efficacy of oxaliplatin on combination with 5-fluorouracil (5-FU) ± folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. Eur J Cancer 2000; 36:2335-2343.
16. Fischel JL, Etienne MC, Formento P, Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4:2529-2535.
17. Morton RF, Goldberg RM, Sargent DJ, Fuchs CS, O'Connell MJ. Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): an NCCTG/CALGB study. Proc Am Soc Clin Oncol 2001; 20:125a (abstr 495).
18. Hochster HS, Chachoua A, Speyer J, Wernz J, Pavlick A, Escalon J, et al. First-line activity of oxaliplatin with weekly bolus 5-FU and low-dose leucovorin (LV) in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001; 20:548.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
20. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburn IJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
21. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9:105-108.
22. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16:2739-2744.
23. Raymond E, Faivre S, Waynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25(suppl 5):4-12.
24. Raymond E, Buquet-fagot C, Djelloul S, Mester J, Cvitkovic F, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 1997; 8:876-885.
25. Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002; 20:2545-2550.